New Zealand seeks feedback on Recall Code review
This article was originally published in SRA
New Zealand's regulatory agency Medsafe is planning to deliver an updated version of its Uniform Recall Procedure for Medicines and Medical Devices (known as the Recall Code) by the end of September 2010 and has issued for consultation draft proposals on the matter1.
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.